Acumen's ACU193 Phase 1 meets endpoints; plaque reduction up to 25%, low ARIA-E rate

Acumen Pharmaceuticals, Inc.

60 mg/kg Q4W cohort showed 25% mean amyloid plaque reduction at day 63; 25 mg/kg Q2W showed 20% at day 70.
Overall ARIA-E rate 10.4% (5/48); symptomatic ARIA-E 2.1% (1/48); no drug-related serious adverse events.
Statistically significant dose-proportional PK and near-maximal target engagement of toxic AβOs in CSF.
Monthly dosing supported by pharmacokinetic and CSF data; company plans FDA interaction in Q4 2023.
INTERCEPT-AD enrolled 60 early-AD participants; results to be submitted for peer-reviewed publication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.